Skip to main content

Advertisement

Table 4 PFS (progression free survival) according to  KRAS  mutation for the two different treatment arms

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

PFS FUFOX CAPOX p-value (log rank)
  n = 105 n = 96 HR (95% CI)
All patients 8.2 months 6.4 months 0.18 0.81 (0.61-1.09)
WT 8.1months 6.4months 0.29
    0.82 (0.56-1.19)
Codon 12 mutation 9.9months 7.0months 0.12
    0.62 (0.33-1.14)
Codon 13 mutation 6.1months 13.3months 0.22
    2.52 (0.54-11.70)
  1. PFS, HR hazard ratio by cox regression, CI confidence interval, WT wild type.